LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Whole-Genome Sequencing Diagnoses Early Infantile Epileptic Encephalopathy

By LabMedica International staff writers
Posted on 30 Aug 2018
Image: The HiSeq X Five System enables ultra-high-throughput whole-genome sequencing at a cost and scale appropriate for large genome centers (Photo courtesy of Illumina).
Image: The HiSeq X Five System enables ultra-high-throughput whole-genome sequencing at a cost and scale appropriate for large genome centers (Photo courtesy of Illumina).
Early infantile epileptic encephalopathy (EIEE) is a rare epilepsy syndrome that causes intractable seizures with multiple seizure types and presents in the first months of life. While the prevalence of EIEE is unclear, and only affects a subset of all infants with seizures, infants with EIEE have serious medical complications.

EIEE patients typically exhibit developmental delay, profound intellectual impairment, and progress to severe psychomotor impairment and early death. Structural brain malformations, birth injury, and inborn errors of metabolism can cause EIEE, but once these causes are accounted for most remaining cases of EIEE are presumed to have a genetic basis.

Scientists at the University of Utah School of Medicine (Salt Lake City, UT, USA) combined deep whole-genome sequencing and a new reference-free de novo variant calling algorithm they developed and applied it to a cohort of 14 patients for whom previous testing led to no diagnosis. The team prioritized the variants they found based on whether they were missense, frameshift, or nonsense variants that fell in known EIEE genes, candidate EIEE genes, or other regions using the GEMINI framework. The team used the Illumina HiSeq X platform to sequence the 14 individuals they recruited into their study, as well both parents of each child, to an average 65X coverage.

The investigators found that for nine patients, they uncovered single, de novo variants in which they had high confidence in pathogenicity. For seven, they found de novo missense mutations affecting ion channel genes like SCNA1, SCN2A, and KCNQ2 that have known links to EIEE. In the two others, they found missense mutations affecting the EEF1A2 and PIGA genes. In two additional patients, they uncovered de novo missense of putative loss-of-function mutations in the protein-coding region of genes that hadn't before been associated with EIEE: DEAF1 and CAMK2G.

The authors concluded that whole-genome sequencing offers a number of advantages for diagnosing monogenic diseases like EIEE. One such advantage, they said is cost. Even though the cost of sequencing remains high, they noted the participants in their study had undergone, in some cases, years of diagnostics tests, each had undergone a minimum of 24 diagnostic tests, costing an average USD 30,866. Whole-genome sequencing, they concluded, could save both time and money. The study was published on August 13, 2018, in the journal npj Genomic Medicine.

Related Links:
University of Utah School of Medicine

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more